James W Russell

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4345644/publications.pdf

Version: 2024-02-01

56
papers

5,701
citations

109137
35
h-index

161609
54
g-index

57
all docs

57
docs citations

57
times ranked

5934
citing authors

#	Article	IF	Citations
1	Strategies for the prevention or reversal of neuropathy. , 2022, , 259-281.		0
2	NAD+ Precursors Repair Mitochondrial Function in Diabetes and Prevent Experimental Diabetic Neuropathy. International Journal of Molecular Sciences, 2022, 23, 4887.	1.8	11
3	The Relationship Between Autonomic Dysfunction of the Gastrointestinal Tract and Emotional Distress in Patients With Systemic Sclerosis. Journal of Clinical Rheumatology, 2021, 27, 11-17.	0.5	7
4	Is there cardiac autonomic neuropathy in prediabetes?. Autonomic Neuroscience: Basic and Clinical, 2020, 229, 102722.	1.4	10
5	Use of non-invasive ventilation to facilitate extubation in a patient with amyotrophic lateral sclerosis with hypercapnic respiratory failure. Neurology International, 2019, 11, 8102.	1.3	1
6	Role of mitochondria in diabetic peripheral neuropathy: Influencing the NAD+-dependent SIRT1â€"PGC-1Î±â€"TFAM pathway. International Review of Neurobiology, 2019, 145, 177-209.	0.9	84
7	Diabetic neuropathy. Nature Reviews Disease Primers, 2019, 5, 41.	18.1	692
8	Physical activity and dietary interventions in diabetic neuropathy: a systematic review. Clinical Autonomic Research, 2019, 29, 443-455.	1.4	45
9	Overexpression of Sirtuin 1 protein in neurons prevents and reverses experimental diabetic neuropathy. Brain, 2019, 142, 3737-3752.	3.7	46
10	Clinician-rated measures for distal symmetrical axonal polyneuropathy. Neurology, 2019, 93, 346-360.	1.5	19
11	Validation of a simple disease-specific, quality-of-life measure for diabetic polyneuropathy. Neurology, 2018, 90, e2034-e2041.	1.5	6
12	Symptoms of Autonomic Dysfunction in Systemic Sclerosis Assessed by the COMPASS-31 Questionnaire. Journal of Rheumatology, 2018, 45, 1145-1152.	1.0	40
13	SIRT1 and NAD+ precursors: Therapeutic targets in multiple sclerosis a review. Journal of Neuroimmunology, 2017, 304, 29-34.	1.1	36
14	Content validity of symptom-based measures for diabetic, chemotherapy, and HIV peripheral neuropathy. Muscle and Nerve, 2017, 55, 366-372.	1.0	24
15	mGluR2/3 activation of the SIRT1 axis preserves mitochondrial function in diabetic neuropathy. Annals of Clinical and Translational Neurology, 2017, 4, 844-858.	1.7	23
16	Diabetes and Cognitive Impairment. Current Diabetes Reports, 2016, 16, 87.	1.7	318
17	The dilemma of diabetes in chronic inflammatory demyelinating polyneuropathy. Journal of Diabetes and Its Complications, 2016, 30, 1401-1407.	1.2	43
18	Mitochondrial transcription factor A regulation of mitochondrial degeneration in experimental diabetic neuropathy. American Journal of Physiology - Endocrinology and Metabolism, 2015, 309, E132-E141.	1.8	46

#	Article	IF	Citations
19	Clinical neuropathy scales in neuropathy associated with impaired glucose tolerance. Journal of Diabetes and Its Complications, 2015, 29, 372-377.	1.2	62
20	Brain diabetic neurodegeneration segregates with low intrinsic aerobic capacity. Annals of Clinical and Translational Neurology, 2014, 1, 589-604.	1.7	39
21	Diabetic Neuropathies. CONTINUUM Lifelong Learning in Neurology, 2014, 20, 1226-1240.	0.4	62
22	PGC-1Î± regulation of mitochondrial degeneration in experimental diabetic neuropathy. Neurobiology of Disease, 2014, 64, 118-130.	2.1	77
23	Potential roles of PINK1 for increased PGC-1Î±-mediated mitochondrial fatty acid oxidation and their associations with Alzheimer disease and diabetes. Mitochondrion, 2014, 18, 41-48.	1.6	59
24	A novel PGC-1Î± isoform in brain localizes to mitochondria and associates with PINK1 and VDAC. Biochemical and Biophysical Research Communications, 2013, 435, 671-677.	1.0	22
25	Overexpression of SIRT1 Protein in Neurons Protects against Experimental Autoimmune Encephalomyelitis through Activation of Multiple SIRT1 Targets. Journal of Immunology, 2013, 190, 4595-4607.	0.4	110
26	Treatment of Diabetic Sensory Polyneuropathy. Current Treatment Options in Neurology, 2011, 13, 143-159.	0.7	124
27	Reliability of quantitative sudomotor axon reflex testing and quantitative sensory testing in neuropathy of impaired glucose regulation. Muscle and Nerve, 2009, 39, 529-535.	1.0	61
28	Alpha-lipoic acid and frataxin: A new indication for an old antioxidant?. Experimental Neurology, 2009, 218, 9-10.	2.0	2
29	Identification of novel targets for PGC-1Î± and histone deacetylase inhibitors in neuroblastoma cells. Biochemical and Biophysical Research Communications, 2009, 379, 578-582.	1.0	31
30	The Utah Early Neuropathy Scale: a sensitive clinical scale for early sensory predominant neuropathy. Journal of the Peripheral Nervous System, 2008, 13, 218-227.	1.4	184
31	Oxidative injury and neuropathy in diabetes and impaired glucose tolerance. Neurobiology of Disease, 2008, 30, 420-429.	2.1	80
32	Regulation of PGC-1Î± and PGC-1Î±-responsive genes with forskolin-induced Schwann cell differentiation. Neuroscience Letters, 2008, 439, 269-274.	1.0	16
33	Transforming growth factor-Î² induces cellular injury in experimental diabetic neuropathy. Experimental Neurology, 2008, 211, 469-479.	2.0	37
34	Metabotropic Glutamate Receptors (mGluRs) and Diabetic Neuropathy. Current Drug Targets, 2008, 9, 85-93.	1.0	25
35	Autonomic dysfunction in obstructive sleep apnea is associated with impaired glucose regulation. Sleep Medicine, 2007, 8, 149-155.	0.8	50
36	SOD2 protects neurons from injury in cell culture and animal models of diabetic neuropathy. Experimental Neurology, 2007, 208, 216-227.	2.0	95

#	Article	IF	Citations
37	Localization of the transcriptional coactivator PGC-1Î± to GABAergic neurons during maturation of the rat brain. Journal of Comparative Neurology, 2007, 502, 1-18.	0.9	96
38	Metabotropic glutamate receptor 3 protects neurons from glucose-induced oxidative injury by increasing intracellular glutathione concentration. Journal of Neurochemistry, 2007, 101, 342-354.	2.1	50
39	Advances in Understanding Drug-Induced Neuropathies. Drug Safety, 2006, 29, 23-30.	1.4	46
40	Does duloxetine safely and effectively reduce the severity of diabetic peripheral neuropathic pain?. Nature Clinical Practice Neurology, 2006, 2, 18-19.	2.7	4
41	Lifestyle Intervention for Pre-Diabetic Neuropathy. Diabetes Care, 2006, 29, 1294-1299.	4.3	509
42	Uncoupling Proteins Prevent Glucose-Induced Neuronal Oxidative Stress and Programmed Cell Death. Diabetes, 2004, 53, 726-734.	0.3	158
43	Protection against glucose-induced neuronal death by NAAG and GCP II inhibition is regulated by mGluR3. Journal of Neurochemistry, 2004, 89, 90-99.	2.1	57
44	Nitrosative Injury and Antioxidant Therapy in the Management of Diabetic Neuropathy. Journal of Investigative Medicine, 2004, 52, 33-44.	0.7	31
45	Metabotropic glutamate receptor regulation of neuronal cell death. Experimental Neurology, 2003, 184, 97-105.	2.0	35
46	Microvascular Complications of Impaired Glucose Tolerance. Diabetes, 2003, 52, 2867-2873.	0.3	321
47	Recent advances in drug-induced neuropathies. Current Opinion in Neurology, 2002, 15, 633-638.	1.8	153
48	Physiological characterization of neuropathy in Fabry's disease. Muscle and Nerve, 2002, 26, 622-629.	1.0	102
49	Oxidative Stress and Programmed Cell Death in Diabetic Neuropathy. Annals of the New York Academy of Sciences, 2002, 959, 368-383.	1.8	274
50	High glucoseâ€induced oxidative stress and mitochondrial dysfunction in neurons. FASEB Journal, 2002, 16, 1738-1748.	0.2	462
51	Impaired glucose tolerance?does it cause neuropathy?. Muscle and Nerve, 2001, 24, 1109-1112.	1.0	63
52	Insulin-Like Growth Factor-I and Over-Expression of Bcl-xL Prevent Glucose-Mediated Apoptosis in Schwann Cells. Journal of Neuropathology and Experimental Neurology, 2001, 60, 147-160.	0.9	119
53	IGF-I Promotes Peripheral Nervous System Myelination. Annals of the New York Academy of Sciences, 1999, 883, 124-130.	1.8	51
54	Neurons Undergo Apoptosis in Animal and Cell Culture Models of Diabetes. Neurobiology of Disease, 1999, 6, 347-363.	2.1	379

#	Article	IF	Citations
55	New insights into the pathogenesis of diabetic neuropathy. Current Opinion in Neurology, 1999, 12, 553-563.	1.8	88
56	Insulin-like growth factor-I prevents apoptosis in neurons after nerve growth factor withdrawal. , 1998, 36, 455-467.		115